Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 5;25(7):207.
doi: 10.1208/s12249-024-02923-6.

Breaking Barriers in Alzheimer's Disease: the Role of Advanced Drug Delivery Systems

Devank Shekho  1 , Ritika Mishra  1 , Raj Kamal  2 , Rohit Bhatia  3 , Ankit Awasthi  4   5
Affiliations
Review

Breaking Barriers in Alzheimer's Disease: the Role of Advanced Drug Delivery Systems

Devank Shekho et al. AAPS PharmSciTech. .

Abstract

Alzheimer's disease (AD), characterized by cognitive impairment, brain plaques, and tangles, is a global health concern affecting millions. It involves the build-up of amyloid-β (Aβ) and tau proteins, the formation of neuritic plaques and neurofibrillary tangles, cholinergic system dysfunction, genetic variations, and mitochondrial dysfunction. Various signaling pathways and metabolic processes are implicated in AD, along with numerous biomarkers used for diagnosis, risk assessment, and research. Despite these, there is no cure or effective treatment for AD. It is critically important to address this immediately to develop novel drug delivery systems (NDDS) capable of targeting the brain and delivering therapeutic agents to modulate the pathological processes of AD. This review summarizes AD, its pathogenesis, related signaling pathways, biomarkers, conventional treatments, the need for NDDS, and their application in AD treatment. It also covers preclinical, clinical, and ongoing trials, patents, and marketed AD formulations.

Keywords: Alzheimer’s disease; NDDS; biomarkers; clinical trials; patents; signaling pathways.

PubMed Disclaimer

References

    1. Angelucci F, et al. Alzheimer’s disease (AD) and mild cognitive impairment (MCI) patients are characterized by increased BDNF serum levels. Curr Alzheimer Res. 2010;7(1):15–20. - DOI
    1. Gulisano W, et al. Role of amyloid-β and tau proteins in Alzheimer’s disease: confuting the amyloid cascade. J Alzheimers Dis. 2018;64(s1):S611–31. - PMC - DOI
    1. Blennow K, de Leon MJ, Zetterberg H. Alzheimer’s Disease Lancet. 2006;368(9533):387–403.
    1. Gallardo G, Holtzman DM. Amyloid-β and Tau at the crossroads of alzheimer's disease. Adv Exp Med Biol. 2019;1184:187–203. https://doi.org/10.1007/978-981-32-9358-8_16 .
    1. Sirkis DW, et al. Dissecting the clinical heterogeneity of early-onset Alzheimer’s disease. Mol Psychiatry. 2022;27(6):2674–88. - PMC - DOI

LinkOut - more resources